Buy Stocks Easy | About Us
October 22, 2021
Buy Stocks Easy | Online Stocks

CLRB


Buy Cellectar Biosciences, Inc. Stock (symbol: CLRB) Easy Online

Company Name: Cellectar Biosciences, Inc.

Symbol: CLRB

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2005

CLRB Current Share Price

Today's CLRB ( Cellectar Biosciences, Inc. ) opening price: $2.1400

Yesterday's CLRB ( Cellectar Biosciences, Inc. ) closing price: $2.1500

Cellectar Biosciences, Inc. Stock ( symbol: CLRB ) Price Chart since IPO (2005):

12 Months Cellectar Biosciences, Inc. Stock ( symbol: CLRB ) Price Chart

Popular Questions about Cellectar Biosciences, Inc. Public Stock ( CLRB )

A: Cellectar Biosciences, Inc. stock symbol (also called stock or share ticker) is CLRB

A: Cellectar Biosciences, Inc. IPO (Initial Public Offering) took place on 2005

A: Cellectar Biosciences, Inc.'s stock (CLRB symbol) price at ther IPO (initial Public Offering) was $2.1400

Q: Is CLRB stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Cellectar Biosciences, Inc. stock (symbol: CLRB) at the beginning of 2019, at the opening share price of $1.9500, with a minimum of $200, by now your shares would be worth $20712 and your profit would be $20512 - SHOW ONLY IF PROFIT.

Buy Cellectar Biosciences, Inc. Stock Easy Online

Cellectar Biosciences, Inc. Stock Ticker Price Chart since IPO:





Cellectar Biosciences, Inc. Stock Price Yesterday



 


Cellectar Biosciences, Inc. Stock Price – Last Week




 


Cellectar Biosciences, Inc. Stock Price – Last Month




 


Cellectar Biosciences, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/16/1960917/0/en/Cellectar-Announces-Data-From-20-Patients-Receiving-a-Single-25mCi-M2-Bolus-Dose-of-CLR-131-in-the-Phase-2-CLOVER-1-Study.html
                            

                                
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

                                
                                
30% overall response rate seen with an average progression free sur...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/09/1957893/0/en/Fractionated-Dosing-of-CLR-131-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma-Presented-at-the-61st-Annual-American-Society-of-Hematology-Conference.html
                            

                                
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference

                                
                                
FLORHAM PARK, N.J., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Cellectar B...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/17/1931131/0/en/Cellectar-Announces-Poster-at-the-2019-AACR-NCI-EORTC-Molecular-Targets-and-Cancer-Therapeutics-Conference-in-Boston.html
                            

                                
Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

                                
                                
FLORHAM PARK, N.J., Oct.  17, 2019  (GLOBE NEWSWIRE) -- Cellectar B...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922485/0/en/Cellectar-Presents-Data-from-DLBCL-Cohort-of-its-Phase-2-CLOVER-1-Study-at-the-European-Society-for-Medical-Oncology-ESMO-Congress.html
                            

                                
Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress

                                
                                
Data showed durable clinical responses, including a 33% overall res...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/24/1919868/0/en/Cellectar-Receives-Orphan-Drug-Designation-from-the-European-Commission-for-CLR-131-in-Multiple-Myeloma.html
                            

                                
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

                                
                                
FLORHAM PARK, N.J., Sept.  24, 2019  (GLOBE NEWSWIRE) -- Cellectar ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/16/1915932/0/en/Cellectar-Presents-Data-from-Cohort-6-of-its-CLR-131-Phase-1-Study-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma.html
                            

                                
Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

                                
                                
Data presented at the 17th International Myeloma Workshop


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/04/1910710/0/en/Cellectar-Announces-Late-Breaker-Poster-Presentation-at-the-17th-International-Myeloma-Workshop.html
                            

                                
Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

                                
                                
FLORHAM PARK, N.J., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Cellectar ...


                            

                        
                    

                


                            

                    


                        
                            http://feeds.benzinga.com/~r/benzinga/~3/exwXDNrbpsw/5-biotech-stocks-with-near-term-catalysts-ahead
                            

                                
5 Biotech Stocks With Near-Term Catalysts Ahead

                                
                                
The biotechnology space is an exciting one with incredible potentia...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/16/1960917/0/en/Cellectar-Announces-Data-From-20-Patients-Receiving-a-Single-25mCi-M2-Bolus-Dose-of-CLR-131-in-the-Phase-2-CLOVER-1-Study.html
                            

                                
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

                                
                                
30% overall response rate seen with an average progression free sur...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/09/1957893/0/en/Fractionated-Dosing-of-CLR-131-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma-Presented-at-the-61st-Annual-American-Society-of-Hematology-Conference.html
                            

                                
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference

                                
                                
FLORHAM PARK, N.J., Dec.  09, 2019  (GLOBE NEWSWIRE) -- Cellectar B...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/17/1931131/0/en/Cellectar-Announces-Poster-at-the-2019-AACR-NCI-EORTC-Molecular-Targets-and-Cancer-Therapeutics-Conference-in-Boston.html
                            

                                
Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

                                
                                
FLORHAM PARK, N.J., Oct.  17, 2019  (GLOBE NEWSWIRE) -- Cellectar B...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922485/0/en/Cellectar-Presents-Data-from-DLBCL-Cohort-of-its-Phase-2-CLOVER-1-Study-at-the-European-Society-for-Medical-Oncology-ESMO-Congress.html
                            

                                
Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress

                                
                                
Data showed durable clinical responses, including a 33% overall res...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/24/1919868/0/en/Cellectar-Receives-Orphan-Drug-Designation-from-the-European-Commission-for-CLR-131-in-Multiple-Myeloma.html
                            

                                
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

                                
                                
FLORHAM PARK, N.J., Sept.  24, 2019  (GLOBE NEWSWIRE) -- Cellectar ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/16/1915932/0/en/Cellectar-Presents-Data-from-Cohort-6-of-its-CLR-131-Phase-1-Study-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma.html
                            

                                
Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

                                
                                
Data presented at the 17th International Myeloma Workshop


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/04/1910710/0/en/Cellectar-Announces-Late-Breaker-Poster-Presentation-at-the-17th-International-Myeloma-Workshop.html
                            

                                
Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

                                
                                
FLORHAM PARK, N.J., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Cellectar ...


                            

                        
                    

                


                            

                    


                        
                            http://feeds.benzinga.com/~r/benzinga/~3/exwXDNrbpsw/5-biotech-stocks-with-near-term-catalysts-ahead
                            

                                
5 Biotech Stocks With Near-Term Catalysts Ahead

                                
                                
The biotechnology space is an exciting one with incredible potentia...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.